Conclusion: Semaglutide reduced CV Deaths/MI/Stroke by 18% with consistency across eGFR categories, uACR levels & KIDGO risk classification. Semaglutidereduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease.